Contents

25 October 2017
Vol 9, Issue 413

About The Cover

Cover image expansion

ONLINE COVER Clearing a Path for PAH Therapy. Occlusion of the lumen of pulmonary arteries, shown in the image here, occurs due to maladaptive vascular remodeling in pulmonary arterial hypertension. Michelakis et al. discovered that treatment with dichloroacetate, a small molecule used as a cancer therapy that inhibits a mitochondrial enzyme, reduced mean pulmonary artery pressure and improved 6-min walk tests in patients with idiopathic pulmonary arterial hypertension. The authors determined that the presence of mutant variants of two genes that encode mitochondrial proteins reduced the efficacy of the treatment, suggesting that clinical trial design could benefit from considering patients' genotypes. [CREDIT: E. MICHELAKIS/UNIVERSITY OF ALBERTA]